Partnerships Maximize Value of HiFi Data and
Complete the Full End-to-End Workflow for PacBio Customers.
MENLO
PARK, Calif., Nov. 1, 2023
/PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of
high-quality, highly accurate sequencing solutions, today announced
the addition of two tertiary analysis partners to PacBio
Compatible. Geneyx and Golden Helix will enable PacBio customers to
leverage PacBio HiFi data for disease research with the Revio,
Sequel II and IIe sequencing systems.
Interpreting sequencing data generally involves primary,
secondary, and tertiary analysis. Tertiary analysis powers
knowledge discovery from variants, usually including annotation,
filtering, and data visualization, and can provide further support
for phasing and analyzing complex events such as structural
variation. These new partnerships are designed to maximize the
value of HiFi data and complete the full end-to-end workflow for
PacBio customers.
"Primary and secondary analysis solutions are available through
our SMRT Analysis Software, the recently released PacBio WGS
Variant Pipeline, and analysis partners such as GoogleHealth, all
of which provide the best quality of data to power biological
interpretation," said Jeff Eidel,
Chief Commercial Officer at PacBio. "Through our new partnerships
with Geneyx and Golden Helix, researchers can accelerate their
discoveries and find solutions from sample to answer across their
HiFi-based workflows."
Publications show that HiFi sequencing finds more structural
variants (SVs) than short reads.1 SVs are important as
they account for much of the genetic diversity between humans and
have been shown to be associated with disease pathogenesis. Our
tertiary analysis partners can further accelerate customers'
interpretation of this important variant class and enable PacBio
customers to create a biological interpretation more easily from
the underlying genomic content of their samples, maximizing the
impact of PacBio sequencing on human health.
"Geneyx takes great pride in its partnership with PacBio. This
collaboration leverages our HiFi sequencing data analysis
expertise, enabling us to provide a comprehensive solution for
long-read whole genome sequencing analysis. Our specialized tools,
including phasing and methylation analysis, are tailored to PacBio
data, simplify the bioinformatics process, and ensure accurate
variant annotation and classification," said David Yizhar, Chief
Executive Officer of Geneyx. "Geneyx serves a diverse global user
base, including PacBio customers. Together, our efforts will
advance the realms of research."
"Long-read sequencing has gained considerable popularity among
our customers. Our clients are looking for reliable identification
of rare variances, improved insights into challenging genomic
regions, and top-notch calls for structural variants," said Dr.
Andreas Scherer, President and Chief
Executive Officer of Golden Helix Inc. "We're excited to
collaborate with PacBio to offer a comprehensive solution to the
market."
PacBio Compatible works with a wide range of organizations
to ensure customers can find verified products that are
complementary to their workflows for PacBio sequencing. Partners
collaborate closely with PacBio scientists to provide seamless
integration and support for customers who are just starting out
with PacBio or expanding their current capabilities.
About PacBio
PacBio (NASDAQ: PACB) is a premier life
science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technologies stem from two highly differentiated core
technologies focused on accuracy, quality and completeness which
include our HiFi long-read sequencing and our SBB® short-read
sequencing technologies. Our products address solutions across a
broad set of research applications including human germline
sequencing, plant and animal sciences, infectious disease and
microbiology, oncology, and other emerging applications. For more
information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and the U.S. Private Securities Litigation Reform Act of
1995. All statements other than statements of historical fact are
forward-looking statements, including statements relating to the
uses, third-party compatibility, cost advantages, quality or
performance of, or benefits or expected benefits of using, PacBio
products or technologies; the ability to leverage PacBio HiFi data
for disease research and provide complete solutions and end-to-end
workflows; the acceleration of discoveries, interpretations and
solutions; the impact of PacBio sequencing on human health; and
other forward-looking statements. Reported results and orders for
any instrument system should not be considered an indication of
future performance. You should not place undue reliance on
forward-looking statements because they are subject to assumptions,
risks, and uncertainties and could cause actual outcomes and
results to differ materially from currently anticipated results,
including, challenges inherent in developing, manufacturing,
launching, marketing and selling new products; rapidly changing
technologies and extensive competition in genomic sequencing;
unanticipated increases in costs or expenses; interruptions or
delays in the supply of components or materials for, or
manufacturing of, PacBio products and products under development;
potential product performance and quality issues and potential
delays in development timelines; the possible loss of key
suppliers; and, third-party claims alleging infringement of patents
and proprietary rights or seeking to invalidate PacBio's patents or
proprietary rights. Additional factors that could materially affect
actual results can be found in PacBio's most recent filings with
the Securities and Exchange Commission, including PacBio's most
recent reports on Forms 8-K, 10-K, and 10-Q, and include those
listed under the caption "Risk Factors." These forward-looking
statements are based on current expectations and speak only as of
the date hereof; except as required by law, PacBio disclaims any
obligation to revise or update these forward-looking statements to
reflect events or circumstances in the future, even if new
information becomes available.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
1 Ebert, P. et al. (2021) Haplotype-resolved diverse
human genomes and integrated analysis of structural variation.
Science. (available here:
https://pubmed.ncbi.nlm.nih.gov/33632895/)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-enables-rare-and-inherited-disease-research-by-adding-tertiary-analysis-partners-to-pacbio-compatible-301973610.html
SOURCE Pacific Biosciences of California, Inc.